The price-to-earnings ratio for Haemonetics Corp. (NYSE: HAE) is above average at 33.86x. The 36-month beta value for HAE is also noteworthy at 0.36. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for HAE is 50.29M, and at present, short sellers hold a 4.05% of that float. The average trading volume of HAE on April 19, 2024 was 468.29K shares.
HAE) stock’s latest price update
Haemonetics Corp. (NYSE: HAE) has seen a decline in its stock price by -1.67 in relation to its previous close of 84.88. However, the company has experienced a -3.54% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-12 that Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors’ optimism for Haemonetics (HAE).
HAE’s Market Performance
Haemonetics Corp. (HAE) has experienced a -3.54% fall in stock performance for the past week, with a 7.68% rise in the past month, and a -0.05% drop in the past quarter. The volatility ratio for the week is 2.11%, and the volatility levels for the past 30 days are at 2.09% for HAE. The simple moving average for the last 20 days is -0.64% for HAE stock, with a simple moving average of -1.61% for the last 200 days.
Analysts’ Opinion of HAE
Many brokerage firms have already submitted their reports for HAE stocks, with Mizuho repeating the rating for HAE by listing it as a “Buy.” The predicted price for HAE in the upcoming period, according to Mizuho is $90 based on the research report published on October 13, 2022 of the previous year 2022.
Citigroup gave a rating of “Neutral” to HAE, setting the target price at $59 in the report published on December 15th of the previous year.
HAE Trading at 6.12% from the 50-Day Moving Average
After a stumble in the market that brought HAE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.39% of loss for the given period.
Volatility was left at 2.09%, however, over the last 30 days, the volatility rate increased by 2.11%, as shares surge +4.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.25% upper at present.
During the last 5 trading sessions, HAE fell by -3.54%, which changed the moving average for the period of 200-days by -0.50% in comparison to the 20-day moving average, which settled at $84.18. In addition, Haemonetics Corp. saw -2.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HAE starting from Strong Stewart W, who sale 228 shares at the price of $90.65 back on Sep 12 ’23. After this action, Strong Stewart W now owns 16,221 shares of Haemonetics Corp., valued at $20,668 using the latest closing price.
Lingamneni Anila, the EVP, Chief Technology Officer of Haemonetics Corp., sale 2,305 shares at $90.00 during a trade that took place back on Sep 11 ’23, which means that Lingamneni Anila is holding 14,495 shares at $207,450 based on the most recent closing price.
Stock Fundamentals for HAE
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.53 for the gross margin
The net margin for Haemonetics Corp. stands at 0.1. The total capital return value is set at 0.09. Equity return is now at value 14.72, with 6.21 for asset returns.
Based on Haemonetics Corp. (HAE), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is 18.67.
Currently, EBITDA for the company is 249.34 million with net debt to EBITDA at 2.62. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The receivables turnover for the company is 6.0for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.
Conclusion
In summary, Haemonetics Corp. (HAE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
